Law Office Of Brodsky & Smith, LLC Announces Investigation Of Par Pharmaceuticals Companies, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Par Pharmaceuticals Companies, Inc (“Par” or the “Company”) (NYSE: PRX) relating to the proposed acquisition by an affiliate of TPG Capital. (“TPG”).

Under the terms of the transaction, Par shareholders will receive only $50.00 in cash for each share of Par stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Par for not acting in the Company’s shareholders' best interests in connection with the sale process to TPG. The transaction may undervalue the Company as Par reported revenue and earnings per share that exceeded analyst projections. In addition, Par reported earnings per share that higher than consensus estimates.

If you own shares of Par stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/454-prx-par-pharmaceuticals-companies-inc.html, or by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010

If you liked this article you might like

Stocks Slide as Economic Worries Return

Stocks Slide as Economic Worries Return

Citigroup, Qualcomm: Stocks to Watch

Citigroup, Qualcomm: Stocks to Watch

Stock Futures Off as Retail Sales Disappoint

Stock Futures Off as Retail Sales Disappoint

Par Pharma CEO: Double-Digit Growth

Par Pharma CEO: Double-Digit Growth

Par Pharmaceutical Companies Stock Hits New 52-Week High (PRX)

Par Pharmaceutical Companies Stock Hits New 52-Week High (PRX)